Hormonal
Semaglutide treatment is associated with a significantly higher risk of diabetic retinopathy complications compared to placebo in patients with type 2 diabetes, particularly those with preexisting retinopathy.
If you have type 2 diabetes and are taking semaglutide, be aware that it may increase the risk of eye problems, especially if you already have diabetic retinopathy. Regular eye exams are essential to monitor for any changes. The cardiovascular benefits of semaglutide are significant, but managing eye health is a critical part of your overall care plan.
Retinopathy complications occurred in 50 patients (3.0%) in the semaglutide group and 29 (1.8%) in the placebo group (hazard ratio, 1.76; 95% CI, 1.11 to 2.78; P = 0.02).
Why this rating
Large-scale, randomized, double-blind, placebo-controlled trial with adjudicated outcomes.
Source
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al. · New England Journal of Medicine · 2016
DOI 10.1056/nejmoa1607141
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →